Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A french multicenter study

Cytometry Part B - Clinical Cytometry

Volumn 88, Issue 1, 2015, Pages 21-29

  Fossat, Chantal ^a   Roussel, Mikael ^b   Arnoux, Isabelle ^a   Asnafi, Vahid ^c   Brouzes, Chantal ^c   Garnache Ottou, Francine ^d   Jacob, Marie Christine ^e   Kuhlein, Emilienne ^f   Macintyre Davi, Elizabeth ^c   Plesa, Adriana ^g   Robillard, Nelly ^h   Tkaczuk, Jean ^f   Ifrah, Norbert ⁱ   Dombret, Herve ^j   Béné, Marie C ^h   Baruchel, Andre ^k   Garand, Richard ^h  

^a TIMONE HOSPITAL   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d ETABLISSEMENT FRANÇAIS DU SANG   (France)

^e GRENOBLE UNIVERSITY HOSPITAL   (France)

^f TOULOUSE UNIVERSITY HOSPITAL   (France)

^g EDOUARD HERRIOT HOSPITAL   (France)

^h NANTES UNIVERSITY HOSPITAL   (France)

ⁱ ANGERS UNIVERSITY HOSPITAL   (France)

^j SAINT LOUIS HOSPITAL   (France)

^k HÔPITAL ROBERT DEBRÉ   (France)

more..

Author keywords

Acute lymphoblastic leukemia; Bone marrow; Flow cytometry; Leukemia associated immunophenotypic pattern; Minimal residual disease; Peripheral blood

Indexed keywords

ASPARAGINASE; CORTICOSTEROID; DAUNORUBICIN; FICOLL; LEUKEMIA ANTIGEN; LEUKEMIA ASSOCIATED IMMUNOPHENOTYPE; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANALYTIC METHOD; ARTICLE; BLOOD; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DATA ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; FLOW CYTOMETRY; FOLLOW UP; FRANCE; HEMOLYSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INFANT; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MULTIPARAMETER FLOW CYTOMETRY; PEDIATRICS; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; CLASSIFICATION; CLINICAL TRIAL; FEMALE; MALE; MONONUCLEAR CELL; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; BONE MARROW; CHILD; DAUNORUBICIN; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; LEUKOCYTES, MONONUCLEAR; MALE; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VINCRISTINE;

EID: 84918589625     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21195     Document Type: Article

References (33)

1. Cavé H, Van Der Werff Ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med 1998;339:591-598.
2. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, Sandlund JT, Rivera GK, Rubnitz JE, Ribeiro RC, Pui CH, Campana D. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000;96:2691-2596.
3. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, Linda S, Martin PL, Pullen DJ, Viswanatha D, Willman CL, Winick N, Camitta BM; Children's Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factor. A Children's Oncology Group study. Blood 2008;111:5477-5485.
4. Brüggemann M, Raff T, Kneba M. Has MRD monitoring superseded other prognostic factors in adult ALL? Blood 2012;120:4470-4481.
5. Patel B, Rai L, Buck G, Richards SM, Mortuza Y, Mitchell W, Gerrard G, Moorman AV, Duke V, Hoffbrand AV, Fielding AK, Goldstone AH, Foroni L. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: Final results of the international trial UKALL XII/ECOG2993. Br J Haematol 2010;148:80-89.
6. Van Der Velden VHJ, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr T, Sutton R, Cave H, Madsen HO, Cayuela JM, Trka J, Eckert C, Foroni L, Zur Stadt U, Beldjord K, Raff T, Van Der Schoot CE, Van Dongen JJ; European Study Group on MRD detection in ALL (ESG-MRD-ALL). Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007;21:604-611.
7. Brüggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, Asnafi V, Baruchel A, Bassan R, Benoit Y, Biondi A, Cavé H, Dombret H, Fielding AK, Foá R, Gökbuget N, Goldstone AH, Goulden N, Henze G, Hoelzer D, Janka-Schaub GE, Macintyre EA, Pieters R, Rambaldi A, Ribera J-M, Schmiegelow K, Spinelli O, Stary J, Von Stackelberg A, Kneba M, Schrappe M, Van Dongen JJM, also on behalf of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010;24:521-535.
8. Campana D, Freitas RO, Coustan Smith E. Detection of residual leukemia with immunological methods-technical developments and clinical implications. Leuk Lymphoma 1994;13:31-34.
9. Campana D, Coustan-Smith E. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002;15:1-19.
10. Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M, Stow P, Su X, Shurtleff S, Pui C-H, Downing JR, Campana D. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2011;117:6267-6276.
11. Denys B, Van Der Sluijs-Gelling AJ, Homburg C, Van Der Schoot CE, De Haas V, Philippé J, Pieters R, Van Dongen JJM, Van Der Velden VHJ. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 2013;27:635-641.
12. Robillard N, Cavé H, Méchinaud F, Guidal C, Garnache-Ottou F, Rorhlich PS, Avet-Loiseau H, Garand R. Four-color flow cytometry bypasses limitations of polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia. Haematologica 2005;90:1516-1523.
13. Garand R, Beldjord K, Cavé H, Fossat C, Arnoux I, Asnafi V, Bertrand Y, Boulland ML, Brouzes C, Clappier E, Delabesse E, Fest T, Garnache-Ottou F, Huguet F, Jacob MC, Kuhlein E, Marty-Grès S, Plesa A, Robillard N, Roussel M, Tkaczuk J, Dombret H, Macintyre E, Ifrah N, Béné MC, Baruchel A. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: A French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL. Leukemia 2013;27:370-376.
14. Gandemer V, Chevret S, Petit A, Vermylen C, Leblanc T, Michel G, Schmitt C, Lejars O, Schneider P, Demeocq F, Bader-Meunier B, Bernaudin F, Perel Y, Auclerc MF, Cayuela JM, Leverger G, Baruchel A; FRALLE Group. Excellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocol. Haematologica 2012;97:1743-1750.
15. Domenech C, Suciu S, De Moerloose B, Mazingue F, Plat G, Ferster A, Uyttebroeck A, Sirvent N, Lutz P, Yakouben K, Munzer M, Röhrlich P, Plantaz D, Millot F, Philippet P, Dastugue N, Girard S, Cavé H, Benoit Y, Bertrandfor Y; Children's Leukemia Group (CLG) of the European Organisation for Research and Treatment of Cancer (EORTC). Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial. Haematologica 2014;99:1220-1227.
16. Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E, Chevallier P, Buzyn A, Delannoy A, Chalandon Y, Vernant JP, Lafage-Pochitaloff M, Chassevent A, Lhéritier V, Macintyre E, Béné MC, Ifrah N, Dombret H. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009;27:911-918.
17. Béné MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, Van't Veer MB. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995;9:1783-1786.
18. Arnoulet C, Béné MC, Durrieu F, Feuillard J, Fossat C, Husson B, Jouault H, Maynadié M, Lacombe F. Four- and five-color flow cytometry analysis of leukocyte differentiation pathways in normal bone marrow: A reference document based on a systematic approach by the GTLLF and GEIL. Cytometry Part B Clin Cytom 2010;78:4-10.
19. McKenna RW, Washington LT, Aquino DB, Picker LJ, Kroft SH. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood 2001;98:2498-2507.
20. Dworzak MN, Froschl G, Printz D, Mann G, Pötschger U, Mühlegger N, Fritsch G, Gadner H; Austrian Berlin-Frankfurt-Münster Study Group. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002;99:1952-1958.
21. Porwit-MacDonald A, Bjorklund E, Lucio P, Van Lochem EG, Mazur J, Parreira A, Van Den Beemd MW, Van Wering ER, Baars E, Gaipa G, Biondi A, Ciudad J, Van Dongen JJ, San Miguel JF, Orfao A. BIOMED-1 concerted action report: flow cytometric characterization of CD71 cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia 2000;14, 816-825.
22. Hedley BD, Keeney M. Technical issues: Flow cytometry and rare event analysis. Int J Lab Hematol 2013;35:344-350.
23. Campana D. Minimal residual disease monitoring in childhood acute lymphoblastic leukemia. Curr Opin Hematol 2012;19:313-318.
24. Dworzak MN, Gaipa G, Schumich A, Maglia O, Ratei R, Veltroni M, Husak Z, Basso G, Karawajew L, Gadner H, Biondi A. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a druginduced regulatory phenomenon. Results of the AIEOP-BFM-ALLFLOW-MRD-Study Group. Cytometry Part B Clin Cytom 2010;78B:147-153.
25. Chen W, Karandikar NJ, McKenna RW, Kroft SH. Stability of leukemiaassociated immunophenotypes in precursor B-lymphoblastic leukemia/lymphoma. A single institution experience. Am J Clin Pathol 2007;127:39-46.
26. Roshal M, Fromm JR, Winter S, Dunsmore K, Wood BL. Immaturity associated antigens are lost during induction for T Cell lymphoblastic leukemia: implications for minimal residual disease detection. Cytometry Part B Clin Cytom 2010;78B:139-146.
27. Loken MR, Chu SC, Fritschle W, Kalnoski M, Wells DA. Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses. Cytometry Part B Clin Cytom 2009;76B:27-36.
28. Brooimans RA, Kraan J, Van Putten W, Cornelissen JJ, Löwenberg B, Gratama JW. Flow cytometric differential of leukocyte populations in normal bone marrow: Influence of peripheral blood contamination. Cytometry Part B Clin Cytom 2009;76B:18-26.
29. Holdrinet RS, Von Egmond J, Wessels JM, Haanen C. A method for quantification of peripheral blood admixture in bone marrow aspirates. Exp Hematol 1980;8:103-107.
30. Roshal M. Detection of minimal residual lymphoblastic leukemia. Int Clin Cytom Soc, ICCS e-Newsletter, 2011; II (1). http://www.cytometry.org/newsletters/eICCS-2-1/article3.php.
31. Rothe G, Schmitz G, for the Working Group on Flow Cytometry and Image Analysis. Consensus document on Leukemia Immunophenotyping. Leukemia 1996;10:877-895.
32. Björklund E, Mazur J, Soderhall S, Porwit-MacDonald A. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia. Leukemia 2003;17:138-148.
33. Coustan-Smith E, Sancho J, Hancock ML, Razzouk BI, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, Pui CH, Campana D. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 2002;100:2399-2402.